Streetbeat News

Analyst Ratings

INTS

Benchmark analyst Robert Wasserman has reiterated a Speculative Buy rating on Intensity Therapeutics (NASDAQ:INTS) and maintained a $12 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 2:25 pm

HSIC

Morgan Stanley analyst Erin Wright has maintained an Underweight rating on Henry Schein (NASDAQ:HSIC) and reduced the price target from $69 to $65.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 2:24 pm

LUNR

Benchmark analyst Josh Sullivan has maintained a Buy rating on Intuitive Machines (NASDAQ:LUNR) but has reduced the price target from $14 to $10.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 2:23 pm

GMED

Morgan Stanley analyst Drew Ranieri has maintained an Equal-Weight rating on Globus Medical (NYSE:GMED) but has reduced the price target from $60 to $53.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 2:22 pm

EXPE

Morgan Stanley analyst Brian Nowak has maintained an Equal-Weight rating on Expedia Group (NASDAQ:EXPE) and increased the price target from $130 to $135.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 2:20 pm

QBTS

Benchmark analyst David Williams has maintained a Buy rating on D-Wave Quantum (NYSE:QBTS) but has reduced the price target from $4 to $2.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 2:20 pm

DKS

Morgan Stanley analyst Simeon Gutman has maintained an Overweight rating on Dick's Sporting Goods (NYSE:DKS) but reduced the price target from $150 to $145.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 2:19 pm

SKYX

Benchmark analyst Michael Legg has reiterated a Buy rating on SKYX Platforms (NASDAQ:SKYX) and maintained a $5 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 2:18 pm

BWA

Morgan Stanley analyst Adam Jonas has maintained an Overweight rating on BorgWarner (NYSE:BWA) but reduced the price target from $47 to $45.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 2:17 pm

NUTX

Benchmark analyst Bill Sutherland has maintained a Buy rating on Nutex Health (NASDAQ:NUTX) but has reduced the price target from $2.5 to $1.5.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 2:16 pm